Experts aren't worried about J&J's vaccine and clusters of bad reactions
Ben Hasty/MediaNews Group/Reading Eagle/Getty Images
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in
- European regulators are investigating J&J's vaccine over a potential link to blood clots - but experts aren't worried;
- 23andMe CEO explains why the company's still prioritizing consumer-first healthcare;
- Pfizer and BioNTech have asked regulators to make their vaccine available to kids 12 to 15.
Johnson & Johnson had a very bad week - but fears of negative reactions and blood clots are likely overblown
- Three US vaccination sites temporarily stopped administering Johnson & Johnson's shot this week.
- The sites reported clusters of adverse reactions, but it's not known whether the shot was the direct cause.
- European regulators are also investigating rare blood clots tied to the vaccine, but experts aren't worried.
Despite 23andMe's declining revenue, CEO Anne Wojcicki said she's committed to consumer-first healthcare 'entirely outside the system'
23andMeCEO Anne Wojcicki reaffirmed her commitment to consumer-first healthcare in a HBR Live event.
- The company's recent SPAC filing demonstrated its plans to further develop its core business: direct-to-consumer genetics.
- "Hands down, I just don't want to be in the system," Wojcicki said of the healthcare industry.
Pfizer and BioNTech have asked US regulators to make their COVID-19 vaccine available to adolescents ages 12 to 15
Pfizerand BioNTech have asked for their COVID-19 vaccineto available for adolescents aged 12 to 15.
- The vaccine showed "100 percent efficacy" in trials with adolescents.
- Moderna and Johnson & Johnson have also started vaccine trials in children.
More stories we're reading:
- 13 years later, Google is again exploring a patient health records tool (Stat News)
- See the presentations that hot healthcare and biotech startups used to raise millions from top VCs (Insider)
- Ginkgo Bioworks is exploring going public via SPAC IPO (Bloomberg)
- A COVID-19 expert shares his simple sports analogy to explain why vaccines work against variants (Insider)
- VillageMD is plotting an IPO that could happen in the third quarter (Bloomberg)
Popular on BI
- A student who accidentally became a millionaire with a cult following after selling his expressionless selfies as NFTs says he feels confused
- After 10-minute grocery delivery, a 15-minute ambulance service grabs investor interest
- Fortune oil maker Adani Wilmar is looking to acquire southern players in edible oil, FMCG industry
- Swiggy is now valued more than Zomato
- OnePlus 10R with MediaTek Dimensity 9000 SoC tipped to launch in India by Q2 end
- IPL 2022: These are the foreign players who are retained by the teams ahead of the auction
- From Adani Green to HAL – these 10 stocks have defied the market meltdown
- Wipro, L&T Infotech, Zee Entertainment, Mindtree among top losers that hit investors’ portfolio in the last one month